Nicotinamide Phosphoribosyltransferase (NAMPT) Inhibitors as Therapeutics: Rationales, Controversies, Clinical Experience

Publisher： Bentham Science Publishers

E-ISSN： 1873-5592|14|6|637-643

ISSN： 1389-4501

Source： Current Drug Targets, Vol.14, Iss.6, 2013-06, pp. : 637-643

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Nicotinamide Phosphoribosyltransferase (Nampt): A Link Between NAD Biology, Metabolism, and Diseases

By  

Current Pharmaceutical Design, Vol. 15, Iss. 1, 2009-01 ,pp. : 20-28

Bentham Science Publishers

Access to resources Recommend Favorite

The Role of Nicotinamide Phosphoribosyltransferase in Cerebral Ischemia

By  

Current Topics in Medicinal Chemistry, Vol. 15, Iss. 21, 2015-01 ,pp. : 2211-2221

Bentham Science Publishers

Access to resources Recommend Favorite

Nicotinamide Adenine Dinucleotide Based Therapeutics

By  

Current Medicinal Chemistry, Vol. 15, Iss. 7, 2008-03 ,pp. : 650-670

Bentham Science Publishers

Access to resources Recommend Favorite

Selective VEGFR Inhibitors for Anticancer Therapeutics in Clinical Use and Clinical Trials

By  

Current Pharmaceutical Design, Vol. 18, Iss. 20, 2012-07 ,pp. : 2921-2935

Bentham Science Publishers

Access to resources Recommend Favorite

Clinical and Experimental Experience with Factor Xa Inhibitors

By Juan F. Viles-Gonzalez   Juan Gaztanaga   Urooj M. Zafar   Valentin Fuster   Juan J. Badimon  

American Journal of Cardiovascular Drugs, Vol. 4, Iss. 6, 2004-01 ,pp. : 379-384

Adis International

Access to resources Recommend Favorite